{"id":8789,"date":"2023-10-30T17:07:28","date_gmt":"2023-10-30T14:07:28","guid":{"rendered":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"},"modified":"2023-10-30T17:07:28","modified_gmt":"2023-10-30T14:07:28","slug":"existe-t-il-un-medicament-qui-eliminera-lobesite","status":"publish","type":"post","link":"https:\/\/urbancare.clinic\/fr\/existe-t-il-un-medicament-qui-eliminera-lobesite\/","title":{"rendered":"Existe-t-il un m\u00e9dicament qui \u00e9liminera l\u2019ob\u00e9sit\u00e9 ?"},"content":{"rendered":"
<\/div>\n

Selon l\u2019Organisation Mondiale de la Sant\u00e9 (OMS), le surpoids et l\u2019ob\u00e9sit\u00e9 sont d\u00e9finis comme \u00ab une accumulation anormale ou excessive de graisse qui pr\u00e9sente un risque pour la sant\u00e9. Un indice de masse corporelle (IMC) sup\u00e9rieur \u00e0 25 est consid\u00e9r\u00e9 comme en surpoids, et sup\u00e9rieur \u00e0 30 est consid\u00e9r\u00e9 comme ob\u00e8se.1<\/sup> Les Centers for Disease Control and Prevention des \u00c9tats-Unis citent une mauvaise alimentation et de faibles niveaux d\u2019activit\u00e9 physique comme facteurs de risque d\u2019ob\u00e9sit\u00e9, affectant environ 421 TP3T des adultes et 201 TP3T des enfants.2<\/sup><\/p>\n

La pr\u00e9valence de l'ob\u00e9sit\u00e9 augmente dans des segments de la population et dans des r\u00e9gions du monde o\u00f9 elle n'\u00e9tait pas un probl\u00e8me auparavant, y compris une multiplication par quatre des taux d'ob\u00e9sit\u00e9 chez les enfants depuis le milieu des ann\u00e9es 1970.1<\/sup> L'approche actuelle de la perte de poids par les prestataires m\u00e9dicaux se concentre d'abord sur le traitement des causes sous-jacentes, puis sur l'optimisation des facteurs li\u00e9s au mode de vie tels que l'alimentation et l'exercice.<\/p>\n

Les options chirurgicales pour traiter l'ob\u00e9sit\u00e9 existent depuis des d\u00e9cennies (par exemple, bypass gastrique, manchon gastrique). Ces derni\u00e8res ann\u00e9es, l\u2019industrie pharmaceutique a introduit un certain nombre de m\u00e9dicaments qui se sont r\u00e9v\u00e9l\u00e9s efficaces pour r\u00e9duire le poids par rapport au placebo. Il existe deux agonistes des r\u00e9cepteurs du peptide-1 de type glucagon (GLP-1) qui ont \u00e9t\u00e9 approuv\u00e9s pour le traitement de l'ob\u00e9sit\u00e9 aux \u00c9tats-Unis : le s\u00e9maglutide et le liraglutide. Ces deux m\u00e9dicaments sont injectables. Les noms de marque du s\u00e9maglutide incluent : Ozempic, Rybelsus et Wegovy. Les noms de marque du liraglutide comprennent\u00a0: Saxenda et Victoza.<\/p>\n

Ces m\u00e9dicaments agissent en permettant \u00e0 votre corps d'utiliser l'insuline plus efficacement, en ralentissant votre digestion et en agissant sur les zones du cerveau impliqu\u00e9es dans la gestion de votre app\u00e9tit.3<\/sup> L'insuline est une hormone qui permet \u00e0 vos cellules d'utiliser le glucose contenu dans vos aliments. Un diagnostic couramment associ\u00e9 \u00e0 l\u2019ob\u00e9sit\u00e9 est le diab\u00e8te de type 2. Dans le diab\u00e8te de type 2, votre corps devient moins capable de produire de l\u2019insuline et moins r\u00e9actif \u00e0 l\u2019insuline qu\u2019il produit. Cela rend difficile le bon fonctionnement de toutes les cellules de votre corps. Les agonistes du GLP-1 peuvent \u00eatre utilis\u00e9s comme option th\u00e9rapeutique pour le diab\u00e8te de type 2 chez certains patients.<\/p>\n

Les effets secondaires les plus courants des agonistes du GLP-1 comprennent les douleurs abdominales, la constipation, les naus\u00e9es, les vomissements et la diarrh\u00e9e. Le ralentissement de la digestion provoqu\u00e9 par ces m\u00e9dicaments est \u00e9galement connu sous le nom de retard de la vidange gastrique. Une vidange gastrique retard\u00e9e conduit les gens \u00e0 se sentir rassasi\u00e9s plus longtemps apr\u00e8s chaque repas.3<\/sup> Des naus\u00e9es peuvent survenir si vous essayez de manger en vous sentant rassasi\u00e9. Les agonistes du GLP-1 ne doivent pas \u00eatre utilis\u00e9s chez les personnes ayant des ant\u00e9c\u00e9dents de pancr\u00e9atite, les personnes atteintes de diab\u00e8te de type 1 et celles qui sont enceintes ou envisagent de le devenir.<\/p>\n

Les agonistes du GLP-1 ne sont pas destin\u00e9s \u00e0 \u00eatre prescrits \u00e0 tout le monde. Les personnes admissibles \u00e0 ce m\u00e9dicament en tant que traitement de gestion du poids doivent avoir un IMC sup\u00e9rieur ou \u00e9gal \u00e0 30. Alternativement, les patients qui ont un IMC sup\u00e9rieur ou \u00e9gal \u00e0 27 ET une autre condition m\u00e9dicale due au surpoids (par exemple, hypertension art\u00e9rielle). , taux de cholest\u00e9rol \u00e9lev\u00e9) seront admissibles.<\/p>\n

Une combinaison de modifications du mode de vie et de m\u00e9dicaments anti-ob\u00e9sit\u00e9 a montr\u00e9 son efficacit\u00e9 dans les essais cliniques.4,5<\/sup> La r\u00e9ponse aux agonistes du GLP-1 varie consid\u00e9rablement d'un patient \u00e0 l'autre. Les gens doivent travailler en \u00e9troite collaboration avec un professionnel de la sant\u00e9 pour trouver la dose optimale du m\u00e9dicament qui leur convient. Non seulement vous devrez surveiller de pr\u00e8s votre poids, mais de nombreux prestataires surveilleront probablement \u00e9galement r\u00e9guli\u00e8rement votre tension art\u00e9rielle et votre fr\u00e9quence cardiaque. Si vous ne perdez pas 4-5% de votre poids corporel apr\u00e8s 3 mois de traitement \u00e0 la dose la plus \u00e9lev\u00e9e tol\u00e9r\u00e9e, votre m\u00e9decin vous aidera probablement \u00e0 arr\u00eater lentement le m\u00e9dicament. Il n\u2019existe actuellement pas de lignes directrices claires pour essayer des agonistes alternatifs du GLP-1 ou d\u2019autres th\u00e9rapies m\u00e9dicamenteuses si le m\u00e9dicament initial n\u2019a pas fonctionn\u00e9. La d\u00e9cision d\u2019essayer d\u2019autres th\u00e9rapies appartiendra \u00e0 chaque patient et prestataire.<\/p>\n

\u00c0 un moment donn\u00e9, les gens cesseront de perdre du poids pendant qu\u2019ils prennent ces m\u00e9dicaments et pourraient avoir besoin de strat\u00e9gies suppl\u00e9mentaires pour perdre davantage de poids. Une prise de poids peut \u00eatre attendue \u00e0 l\u2019arr\u00eat de ces m\u00e9dicaments. Cette prise de poids se produit parce que notre corps travaille tr\u00e8s dur pour maintenir son poids souhait\u00e9. Notre capacit\u00e9 de base \u00e0 br\u00fbler des calories diminuera avec la perte de poids6<\/sup> et les hormones qui nous indiquent que nous avons faim vont s\u2019emballer pour revenir \u00e0 notre point de consigne interne.7<\/sup> Les scientifiques continuent d\u2019\u00e9tudier les effets \u00e0 long terme de la perte de poids sur notre m\u00e9tabolisme et nos hormones, car la plupart des gens reprennent le poids perdu en 2 \u00e0 3 ans.8<\/sup> Par cons\u00e9quent, si une perte de poids est obtenue avec un agoniste du GLP-1, sa poursuite \u00e0 plus long terme peut \u00eatre n\u00e9cessaire pour maintenir les b\u00e9n\u00e9fices.<\/p>\n

Ces m\u00e9dicaments vous conviennent-ils\u00a0? Vous devrez consulter votre fournisseur de soins de sant\u00e9 pour d\u00e9terminer si vous \u00eates admissible \u00e0 ces m\u00e9dicaments et s'ils vous conviennent.<\/p>\n

Ouvrages cit\u00e9s:<\/p>\n

1. Ob\u00e9sit\u00e9 (who.int)<\/a>
2. HOP 2023 | NOFO | DNPAO | CDC<\/a>
3. Agonistes des r\u00e9cepteurs du peptide 1 de type glucagon \u2013 StatPearls \u2013 Biblioth\u00e8que NCBI (nih.gov)<\/a>
4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association des traitements pharmacologiques de l'ob\u00e9sit\u00e9 avec perte de poids et \u00e9v\u00e9nements ind\u00e9sirables\u00a0: une revue syst\u00e9matique et une m\u00e9ta-analyse. JAMA. 14 juin 2016;315(22):2424-34. est ce que je: 10.1001\/jama.2016.7602. Erratum dans : JAMA. 6 septembre 2016;316(9):995. PMID\u00a0: 27299618\u00a0; PMCID\u00a0: PMC5617638.<\/a>
5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT\u00a0; \u00c9TAPE 8 Enqu\u00eateurs. Effet du s\u00e9maglutide sous-cutan\u00e9 hebdomadaire par rapport au liraglutide quotidien sur le poids corporel chez les adultes en surpoids ou ob\u00e8ses sans diab\u00e8te\u00a0: l'essai clinique randomis\u00e9 STEP 8. JAMA. 11 janvier 2022;327(2):138-150. est ce que je: 10.1001\/jama.2021.23619. PMID\u00a0: 35015037\u00a0; PMCID\u00a0: PMC8753508.<\/a>
6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Persistance \u00e0 long terme de la thermogen\u00e8se adaptative chez les sujets ayant maintenu un poids corporel r\u00e9duit. Suis J Clin Nutr. Octobre 2008\u00a0; 88(4) :906-12. est ce que je: 10.1093\/ajcn\/88.4.906. PMID\u00a0: 18842775.<\/a>
7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Persistance \u00e0 long terme des adaptations hormonales \u00e0 la perte de poids. N Engl J Med. 27 octobre 2011;365(17):1597-604. est ce que je: 10.1056\/NEJMoa1105816. PMID\u00a0: 22029981.<\/a>
8. Maintenir la perte de poids | M\u00e9decine Johns Hopkins<\/a><\/p>\n

Source quotidienne m\u00e9dicale<\/a><\/p>\n

","protected":false},"excerpt":{"rendered":"

<\/div>\n

Selon l\u2019Organisation Mondiale de la Sant\u00e9 (OMS), le surpoids et l\u2019ob\u00e9sit\u00e9 sont d\u00e9finis comme \u00ab une accumulation anormale ou excessive de graisse qui pr\u00e9sente un risque pour la sant\u00e9. Un indice de masse corporelle (IMC) sup\u00e9rieur \u00e0 25 est consid\u00e9r\u00e9 comme en surpoids, et sup\u00e9rieur \u00e0 30 est consid\u00e9r\u00e9 comme ob\u00e8se.1<\/sup> Les Centers for Disease Control and Prevention des \u00c9tats-Unis citent une mauvaise alimentation et de faibles niveaux d\u2019activit\u00e9 physique comme facteurs de risque d\u2019ob\u00e9sit\u00e9, affectant environ 421 TP3T des adultes et 201 TP3T des enfants.2<\/sup><\/p>\n

La pr\u00e9valence de l'ob\u00e9sit\u00e9 augmente dans des segments de la population et dans des r\u00e9gions du monde o\u00f9 elle n'\u00e9tait pas un probl\u00e8me auparavant, y compris une multiplication par quatre des taux d'ob\u00e9sit\u00e9 chez les enfants depuis le milieu des ann\u00e9es 1970.1<\/sup> L'approche actuelle de la perte de poids par les prestataires m\u00e9dicaux se concentre d'abord sur le traitement des causes sous-jacentes, puis sur l'optimisation des facteurs li\u00e9s au mode de vie tels que l'alimentation et l'exercice.<\/p>\n

Les options chirurgicales pour traiter l'ob\u00e9sit\u00e9 existent depuis des d\u00e9cennies (par exemple, bypass gastrique, manchon gastrique). Ces derni\u00e8res ann\u00e9es, l\u2019industrie pharmaceutique a introduit un certain nombre de m\u00e9dicaments qui se sont r\u00e9v\u00e9l\u00e9s efficaces pour r\u00e9duire le poids par rapport au placebo. Il existe deux agonistes des r\u00e9cepteurs du peptide-1 de type glucagon (GLP-1) qui ont \u00e9t\u00e9 approuv\u00e9s pour le traitement de l'ob\u00e9sit\u00e9 aux \u00c9tats-Unis : le s\u00e9maglutide et le liraglutide. Ces deux m\u00e9dicaments sont injectables. Les noms de marque du s\u00e9maglutide incluent : Ozempic, Rybelsus et Wegovy. Les noms de marque du liraglutide comprennent\u00a0: Saxenda et Victoza.<\/p>\n

Ces m\u00e9dicaments agissent en permettant \u00e0 votre corps d'utiliser l'insuline plus efficacement, en ralentissant votre digestion et en agissant sur les zones du cerveau impliqu\u00e9es dans la gestion de votre app\u00e9tit.3<\/sup> L'insuline est une hormone qui permet \u00e0 vos cellules d'utiliser le glucose contenu dans vos aliments. Un diagnostic couramment associ\u00e9 \u00e0 l\u2019ob\u00e9sit\u00e9 est le diab\u00e8te de type 2. Dans le diab\u00e8te de type 2, votre corps devient moins capable de produire de l\u2019insuline et moins r\u00e9actif \u00e0 l\u2019insuline qu\u2019il produit. Cela rend difficile le bon fonctionnement de toutes les cellules de votre corps. Les agonistes du GLP-1 peuvent \u00eatre utilis\u00e9s comme option th\u00e9rapeutique pour le diab\u00e8te de type 2 chez certains patients.<\/p>\n

Les effets secondaires les plus courants des agonistes du GLP-1 comprennent les douleurs abdominales, la constipation, les naus\u00e9es, les vomissements et la diarrh\u00e9e. Le ralentissement de la digestion provoqu\u00e9 par ces m\u00e9dicaments est \u00e9galement connu sous le nom de retard de la vidange gastrique. Une vidange gastrique retard\u00e9e conduit les gens \u00e0 se sentir rassasi\u00e9s plus longtemps apr\u00e8s chaque repas.3<\/sup> Des naus\u00e9es peuvent survenir si vous essayez de manger en vous sentant rassasi\u00e9. Les agonistes du GLP-1 ne doivent pas \u00eatre utilis\u00e9s chez les personnes ayant des ant\u00e9c\u00e9dents de pancr\u00e9atite, les personnes atteintes de diab\u00e8te de type 1 et celles qui sont enceintes ou envisagent de le devenir.<\/p>\n

Les agonistes du GLP-1 ne sont pas destin\u00e9s \u00e0 \u00eatre prescrits \u00e0 tout le monde. Les personnes admissibles \u00e0 ce m\u00e9dicament en tant que traitement de gestion du poids doivent avoir un IMC sup\u00e9rieur ou \u00e9gal \u00e0 30. Alternativement, les patients qui ont un IMC sup\u00e9rieur ou \u00e9gal \u00e0 27 ET une autre condition m\u00e9dicale due au surpoids (par exemple, hypertension art\u00e9rielle). , taux de cholest\u00e9rol \u00e9lev\u00e9) seront admissibles.<\/p>\n

Une combinaison de modifications du mode de vie et de m\u00e9dicaments anti-ob\u00e9sit\u00e9 a montr\u00e9 son efficacit\u00e9 dans les essais cliniques.4,5<\/sup> La r\u00e9ponse aux agonistes du GLP-1 varie consid\u00e9rablement d'un patient \u00e0 l'autre. Les gens doivent travailler en \u00e9troite collaboration avec un professionnel de la sant\u00e9 pour trouver la dose optimale du m\u00e9dicament qui leur convient. Non seulement vous devrez surveiller de pr\u00e8s votre poids, mais de nombreux prestataires surveilleront probablement \u00e9galement r\u00e9guli\u00e8rement votre tension art\u00e9rielle et votre fr\u00e9quence cardiaque. Si vous ne perdez pas 4-5% de votre poids corporel apr\u00e8s 3 mois de traitement \u00e0 la dose la plus \u00e9lev\u00e9e tol\u00e9r\u00e9e, votre m\u00e9decin vous aidera probablement \u00e0 arr\u00eater lentement le m\u00e9dicament. Il n\u2019existe actuellement pas de lignes directrices claires pour essayer des agonistes alternatifs du GLP-1 ou d\u2019autres th\u00e9rapies m\u00e9dicamenteuses si le m\u00e9dicament initial n\u2019a pas fonctionn\u00e9. La d\u00e9cision d\u2019essayer d\u2019autres th\u00e9rapies appartiendra \u00e0 chaque patient et prestataire.<\/p>\n

\u00c0 un moment donn\u00e9, les gens cesseront de perdre du poids pendant qu\u2019ils prennent ces m\u00e9dicaments et pourraient avoir besoin de strat\u00e9gies suppl\u00e9mentaires pour perdre davantage de poids. Une prise de poids peut \u00eatre attendue \u00e0 l\u2019arr\u00eat de ces m\u00e9dicaments. Cette prise de poids se produit parce que notre corps travaille tr\u00e8s dur pour maintenir son poids souhait\u00e9. Notre capacit\u00e9 de base \u00e0 br\u00fbler des calories diminuera avec la perte de poids6<\/sup> et les hormones qui nous indiquent que nous avons faim vont s\u2019emballer pour revenir \u00e0 notre point de consigne interne.7<\/sup> Les scientifiques continuent d\u2019\u00e9tudier les effets \u00e0 long terme de la perte de poids sur notre m\u00e9tabolisme et nos hormones, car la plupart des gens reprennent le poids perdu en 2 \u00e0 3 ans.8<\/sup> Par cons\u00e9quent, si une perte de poids est obtenue avec un agoniste du GLP-1, sa poursuite \u00e0 plus long terme peut \u00eatre n\u00e9cessaire pour maintenir les b\u00e9n\u00e9fices.<\/p>\n

Ces m\u00e9dicaments vous conviennent-ils\u00a0? Vous devrez consulter votre fournisseur de soins de sant\u00e9 pour d\u00e9terminer si vous \u00eates admissible \u00e0 ces m\u00e9dicaments et s'ils vous conviennent.<\/p>\n

Ouvrages cit\u00e9s:<\/p>\n

1. Ob\u00e9sit\u00e9 (who.int)<\/a>
2. HOP 2023 | NOFO | DNPAO | CDC<\/a>
3. Agonistes des r\u00e9cepteurs du peptide 1 de type glucagon \u2013 StatPearls \u2013 Biblioth\u00e8que NCBI (nih.gov)<\/a>
4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association des traitements pharmacologiques de l'ob\u00e9sit\u00e9 avec perte de poids et \u00e9v\u00e9nements ind\u00e9sirables\u00a0: une revue syst\u00e9matique et une m\u00e9ta-analyse. JAMA. 14 juin 2016;315(22):2424-34. est ce que je: 10.1001\/jama.2016.7602. Erratum dans : JAMA. 6 septembre 2016;316(9):995. PMID\u00a0: 27299618\u00a0; PMCID\u00a0: PMC5617638.<\/a>
5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT\u00a0; \u00c9TAPE 8 Enqu\u00eateurs. Effet du s\u00e9maglutide sous-cutan\u00e9 hebdomadaire par rapport au liraglutide quotidien sur le poids corporel chez les adultes en surpoids ou ob\u00e8ses sans diab\u00e8te\u00a0: l'essai clinique randomis\u00e9 STEP 8. JAMA. 11 janvier 2022;327(2):138-150. est ce que je: 10.1001\/jama.2021.23619. PMID\u00a0: 35015037\u00a0; PMCID\u00a0: PMC8753508.<\/a>
6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Persistance \u00e0 long terme de la thermogen\u00e8se adaptative chez les sujets ayant maintenu un poids corporel r\u00e9duit. Suis J Clin Nutr. Octobre 2008\u00a0; 88(4) :906-12. est ce que je: 10.1093\/ajcn\/88.4.906. PMID\u00a0: 18842775.<\/a>
7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Persistance \u00e0 long terme des adaptations hormonales \u00e0 la perte de poids. N Engl J Med. 27 octobre 2011;365(17):1597-604. est ce que je: 10.1056\/NEJMoa1105816. PMID\u00a0: 22029981.<\/a>
8. Maintenir la perte de poids | M\u00e9decine Johns Hopkins<\/a><\/p>","protected":false},"author":2,"featured_media":8790,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"Default","format":"standard","meta":{"fifu_image_url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","fifu_image_alt":"","footnotes":""},"categories":[27],"tags":[],"class_list":["post-8789","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-blog"],"yoast_head":"\nIs There A Medication That will Eliminate Obesity? - Urban Care Clinic<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/urbancare.clinic\/fr\/existe-t-il-un-medicament-qui-eliminera-lobesite\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Is There A Medication That will Eliminate Obesity? - Urban Care Clinic\" \/>\n<meta property=\"og:description\" content=\"According to the World Health Organization (WHO), overweight and obesity are defined as "abnormal or excessive fat accumulation that presents a health risk. A body mass index (BMI) over 25 is considered overweight, and over 30 is obese."1 The United States Centers for Disease Control and Prevention cites poor diet and low physical activity levels as risk factors for obesity, affecting approximately 42% of adults and 20% of children.2The prevalence of obesity is climbing in segments of the population and areas of the world in which it has not previously been a concern, including a fourfold increase in obesity rates in children since the mid-1970's.1 The current approach to weight loss by medical providers focuses initially on treating underlying causes and then on optimizing lifestyle factors such as diet and exercise.Surgical options for treating obesity have been around for decades (eg. Gastric bypass, gastric sleeve). In recent years, the pharmaceutical industry has introduced a number of medications that have been proven effective at reducing weight compared to placebo. There are two glucagon-like peptide-1 (GLP-1) receptor agonists that have been approved for the treatment of obesity in the United States: semaglutide and liraglutide. Both of these medications are injectable. The brand names for semaglutide include: Ozempic, Rybelsus, and Wegovy. The brand names for liraglutide include: Saxenda and Victoza.These medications work by allowing your body to use insulin more effectively, slowing down your digestion, and by acting on areas of the brain involved in managing your appetite.3 Insulin is a hormone that allows your cells to use the glucose from your food. One diagnosis commonly associated with obesity is type 2 Diabetes. In type 2 Diabetes, your body becomes less able to make insulin and less responsive to the insulin it does make. This makes it difficult for all your body's cells to function properly. The GLP-1 agonists can be used as a treatment option for type 2 Diabetes in certain patients.The most common side effects from GLP-1 agonists include abdominal pain, constipation, nausea, vomiting, and diarrhea. The slowed digestion caused by these medications is also known as delayed gastric emptying. Delayed gastric emptying leads to people feeling fuller after each meal for longer.3 Nausea can result if you attempt to eat while feeling full. GLP-1agonists should not be used in people with a history of pancreatitis, people with type 1 diabetes, and those who are pregnant or planning to become pregnant.GLP-1 agonists are not meant to be prescribed for everyone. People who qualify for this medication as a weight management treatment must have a BMI of greater than or equal to 30. Alternatively, patients who have a BMI greater than or equal to 27 AND another medical condition due to being overweight (eg. High blood pressure, high cholesterol) will qualify.A combination of lifestyle modifications and anti-obesity medications has shown efficacy in clinical trials.4,5 The response to GLP-1 agonists varies widely between patients. People need to work closely with a healthcare provider to find the optimal dose of the medication that is right for them. Not only will you need to have your weight closely monitored, but many providers will likely also monitor your blood pressure and heart rate regularly. If you do not lose 4-5% of your body weight after 3 months of medication at the highest tolerated dose, your healthcare provider will likely assist you in slowly stopping the medication. There are not currently clear guidelines for trying alternative GLP-1 agonists or other medication therapies if the initial medication did not work. The decision to trial other therapies will be up to each individual patient and provider.At a certain point, people will stop losing weight while on these medications and may need additional strategies for more weight loss. Weight gain can be expected when these medications are stopped. This weight gain occurs because our bodies work very hard to maintain their preferred weight. Our baseline ability to burn calories will decrease with weight loss6 and the hormones that tell us we are hungry will go into overdrive to return to our internal set point.7 Scientists continue to study the long-term effects of weight loss on our metabolism and hormones because most people regain lost weight within 2-3 years.8 Therefore, if weight loss is successfully achieved with a GLP-1 agonist, continuing them longer term may be necessary to maintain the benefits.Are these medications right for you? You will need to consult your healthcare provider to determine if you qualify for these medications and if they are right for you.Works Cited:1. Obesity (who.int)2. HOP 2023 | NOFO | DNPAO | CDC3. Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf (nih.gov)4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001\/jama.2016.7602. Erratum in: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001\/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008 Oct;88(4):906-12. doi: 10.1093\/ajcn\/88.4.906. PMID: 18842775.7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056\/NEJMoa1105816. PMID: 22029981.8. Maintaining Weight Loss | Johns Hopkins Medicine\" \/>\n<meta property=\"og:url\" content=\"https:\/\/urbancare.clinic\/fr\/existe-t-il-un-medicament-qui-eliminera-lobesite\/\" \/>\n<meta property=\"og:site_name\" content=\"Urban Care Clinic\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/urbancarezanzibar\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-30T14:07:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\" \/>\n<meta name=\"author\" content=\"Urban Care Clinic\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"Urban Care Clinic\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\"},\"author\":{\"name\":\"Urban Care Clinic\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c\"},\"headline\":\"Is There A Medication That will Eliminate Obesity?\",\"datePublished\":\"2023-10-30T14:07:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\"},\"wordCount\":948,\"publisher\":{\"@id\":\"https:\/\/urbancare.clinic\/#organization\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"articleSection\":[\"Medical Daily\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\",\"url\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\",\"name\":\"Is There A Medication That will Eliminate Obesity? - Urban Care Clinic\",\"isPartOf\":{\"@id\":\"https:\/\/urbancare.clinic\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"datePublished\":\"2023-10-30T14:07:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage\",\"url\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"contentUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg\",\"caption\":\"Is There A Medication That will Eliminate Obesity?\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/urbancare.clinic\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Is There A Medication That will Eliminate Obesity?\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/urbancare.clinic\/#website\",\"url\":\"https:\/\/urbancare.clinic\/\",\"name\":\"Urban Care Clinic\",\"description\":\"Your Medical Healthcare Clinic in Zanzibar\",\"publisher\":{\"@id\":\"https:\/\/urbancare.clinic\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/urbancare.clinic\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/urbancare.clinic\/#organization\",\"name\":\"Urban Care Clinic Zanzibar\",\"alternateName\":\"Urban Care Clinic\",\"url\":\"https:\/\/urbancare.clinic\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png\",\"contentUrl\":\"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png\",\"width\":500,\"height\":500,\"caption\":\"Urban Care Clinic Zanzibar\"},\"image\":{\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/urbancarezanzibar\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c\",\"name\":\"Urban Care Clinic\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/urbancare.clinic\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g\",\"caption\":\"Urban Care Clinic\"},\"url\":\"https:\/\/urbancare.clinic\/fr\/author\/urban-care-clinic\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Existe-t-il un m\u00e9dicament qui \u00e9liminera l\u2019ob\u00e9sit\u00e9 ? - Clinique de soins urbains","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/urbancare.clinic\/fr\/existe-t-il-un-medicament-qui-eliminera-lobesite\/","og_locale":"fr_FR","og_type":"article","og_title":"Is There A Medication That will Eliminate Obesity? - Urban Care Clinic","og_description":"According to the World Health Organization (WHO), overweight and obesity are defined as \"abnormal or excessive fat accumulation that presents a health risk. A body mass index (BMI) over 25 is considered overweight, and over 30 is obese.\"1 The United States Centers for Disease Control and Prevention cites poor diet and low physical activity levels as risk factors for obesity, affecting approximately 42% of adults and 20% of children.2The prevalence of obesity is climbing in segments of the population and areas of the world in which it has not previously been a concern, including a fourfold increase in obesity rates in children since the mid-1970's.1 The current approach to weight loss by medical providers focuses initially on treating underlying causes and then on optimizing lifestyle factors such as diet and exercise.Surgical options for treating obesity have been around for decades (eg. Gastric bypass, gastric sleeve). In recent years, the pharmaceutical industry has introduced a number of medications that have been proven effective at reducing weight compared to placebo. There are two glucagon-like peptide-1 (GLP-1) receptor agonists that have been approved for the treatment of obesity in the United States: semaglutide and liraglutide. Both of these medications are injectable. The brand names for semaglutide include: Ozempic, Rybelsus, and Wegovy. The brand names for liraglutide include: Saxenda and Victoza.These medications work by allowing your body to use insulin more effectively, slowing down your digestion, and by acting on areas of the brain involved in managing your appetite.3 Insulin is a hormone that allows your cells to use the glucose from your food. One diagnosis commonly associated with obesity is type 2 Diabetes. In type 2 Diabetes, your body becomes less able to make insulin and less responsive to the insulin it does make. This makes it difficult for all your body's cells to function properly. The GLP-1 agonists can be used as a treatment option for type 2 Diabetes in certain patients.The most common side effects from GLP-1 agonists include abdominal pain, constipation, nausea, vomiting, and diarrhea. The slowed digestion caused by these medications is also known as delayed gastric emptying. Delayed gastric emptying leads to people feeling fuller after each meal for longer.3 Nausea can result if you attempt to eat while feeling full. GLP-1agonists should not be used in people with a history of pancreatitis, people with type 1 diabetes, and those who are pregnant or planning to become pregnant.GLP-1 agonists are not meant to be prescribed for everyone. People who qualify for this medication as a weight management treatment must have a BMI of greater than or equal to 30. Alternatively, patients who have a BMI greater than or equal to 27 AND another medical condition due to being overweight (eg. High blood pressure, high cholesterol) will qualify.A combination of lifestyle modifications and anti-obesity medications has shown efficacy in clinical trials.4,5 The response to GLP-1 agonists varies widely between patients. People need to work closely with a healthcare provider to find the optimal dose of the medication that is right for them. Not only will you need to have your weight closely monitored, but many providers will likely also monitor your blood pressure and heart rate regularly. If you do not lose 4-5% of your body weight after 3 months of medication at the highest tolerated dose, your healthcare provider will likely assist you in slowly stopping the medication. There are not currently clear guidelines for trying alternative GLP-1 agonists or other medication therapies if the initial medication did not work. The decision to trial other therapies will be up to each individual patient and provider.At a certain point, people will stop losing weight while on these medications and may need additional strategies for more weight loss. Weight gain can be expected when these medications are stopped. This weight gain occurs because our bodies work very hard to maintain their preferred weight. Our baseline ability to burn calories will decrease with weight loss6 and the hormones that tell us we are hungry will go into overdrive to return to our internal set point.7 Scientists continue to study the long-term effects of weight loss on our metabolism and hormones because most people regain lost weight within 2-3 years.8 Therefore, if weight loss is successfully achieved with a GLP-1 agonist, continuing them longer term may be necessary to maintain the benefits.Are these medications right for you? You will need to consult your healthcare provider to determine if you qualify for these medications and if they are right for you.Works Cited:1. Obesity (who.int)2. HOP 2023 | NOFO | DNPAO | CDC3. Glucagon-Like Peptide-1 Receptor Agonists - StatPearls - NCBI Bookshelf (nih.gov)4. Khera R, Murad MH, Chandar AK, Dulai PS, Wang Z, Prokop LJ, Loomba R, Camilleri M, Singh S. Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events: A Systematic Review and Meta-analysis. JAMA. 2016 Jun 14;315(22):2424-34. doi: 10.1001\/jama.2016.7602. Erratum in: JAMA. 2016 Sep 6;316(9):995. PMID: 27299618; PMCID: PMC5617638.5. Rubino DM, Greenway FL, Khalid U, O'Neil PM, Rosenstock J, S\u00f8rrig R, Wadden TA, Wizert A, Garvey WT; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022 Jan 11;327(2):138-150. doi: 10.1001\/jama.2021.23619. PMID: 35015037; PMCID: PMC8753508.6. Rosenbaum M, Hirsch J, Gallagher DA, Leibel RL. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008 Oct;88(4):906-12. doi: 10.1093\/ajcn\/88.4.906. PMID: 18842775.7. Sumithran P, Prendergast LA, Delbridge E, Purcell K, Shulkes A, Kriketos A, Proietto J. Long-term persistence of hormonal adaptations to weight loss. N Engl J Med. 2011 Oct 27;365(17):1597-604. doi: 10.1056\/NEJMoa1105816. PMID: 22029981.8. Maintaining Weight Loss | Johns Hopkins Medicine","og_url":"https:\/\/urbancare.clinic\/fr\/existe-t-il-un-medicament-qui-eliminera-lobesite\/","og_site_name":"Urban Care Clinic","article_publisher":"https:\/\/www.facebook.com\/urbancarezanzibar","article_published_time":"2023-10-30T14:07:28+00:00","og_image":[{"url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","type":"","width":"","height":""}],"author":"Urban Care Clinic","twitter_card":"summary_large_image","twitter_image":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","twitter_misc":{"\u00c9crit par":"Urban Care Clinic","Dur\u00e9e de lecture estim\u00e9e":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#article","isPartOf":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"},"author":{"name":"Urban Care Clinic","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c"},"headline":"Is There A Medication That will Eliminate Obesity?","datePublished":"2023-10-30T14:07:28+00:00","mainEntityOfPage":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"},"wordCount":948,"publisher":{"@id":"https:\/\/urbancare.clinic\/#organization"},"image":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","articleSection":["Medical Daily"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/","url":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/","name":"Existe-t-il un m\u00e9dicament qui \u00e9liminera l\u2019ob\u00e9sit\u00e9 ? - Clinique de soins urbains","isPartOf":{"@id":"https:\/\/urbancare.clinic\/#website"},"primaryImageOfPage":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage"},"image":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage"},"thumbnailUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","datePublished":"2023-10-30T14:07:28+00:00","breadcrumb":{"@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#primaryimage","url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","contentUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2023\/10\/is-there-a-medication-that-will-eliminate-obesity.jpg","caption":"Is There A Medication That will Eliminate Obesity?"},{"@type":"BreadcrumbList","@id":"https:\/\/urbancare.clinic\/is-there-a-medication-that-will-eliminate-obesity\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/urbancare.clinic\/"},{"@type":"ListItem","position":2,"name":"Is There A Medication That will Eliminate Obesity?"}]},{"@type":"WebSite","@id":"https:\/\/urbancare.clinic\/#website","url":"https:\/\/urbancare.clinic\/","name":"Clinique de soins urbains","description":"Votre clinique de soins m\u00e9dicaux \u00e0 Zanzibar","publisher":{"@id":"https:\/\/urbancare.clinic\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/urbancare.clinic\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/urbancare.clinic\/#organization","name":"Clinique de soins urbains Zanzibar","alternateName":"Urban Care Clinic","url":"https:\/\/urbancare.clinic\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/","url":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png","contentUrl":"https:\/\/urbancare.clinic\/wp-content\/uploads\/2022\/07\/Urban-Care-Clinic-Logo-Trans-512x512-1.png","width":500,"height":500,"caption":"Urban Care Clinic Zanzibar"},"image":{"@id":"https:\/\/urbancare.clinic\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/urbancarezanzibar"]},{"@type":"Person","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/f286c4d84be896d302aceda3ed7e789c","name":"Clinique de soins urbains","image":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/urbancare.clinic\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/8f8b5f9c42679ce61ae24fd31561a4574502595c4b3428a4fdf92d929bf09352?s=96&d=mm&r=g","caption":"Urban Care Clinic"},"url":"https:\/\/urbancare.clinic\/fr\/author\/urban-care-clinic\/"}]}},"_links":{"self":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/posts\/8789","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/comments?post=8789"}],"version-history":[{"count":0,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/posts\/8789\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/media\/8790"}],"wp:attachment":[{"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/media?parent=8789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/categories?post=8789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/urbancare.clinic\/fr\/wp-json\/wp\/v2\/tags?post=8789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}